Interestingly, daily treatment with PPi alone did not worsen CKD-related bone formation/-mineralization defects in our study as one may reasonably assume that in the absence of a TNAP inhibitor, the enzymatic TNAP-mediated PPi breakdown remains intact in the bone, through which the PPi/Pi ratio is kept stable. This evidence concerns the gene ALPL and chronic kidney disease.